CY1124865T1 - Νεες ενωσεις - Google Patents

Νεες ενωσεις

Info

Publication number
CY1124865T1
CY1124865T1 CY20211101110T CY211101110T CY1124865T1 CY 1124865 T1 CY1124865 T1 CY 1124865T1 CY 20211101110 T CY20211101110 T CY 20211101110T CY 211101110 T CY211101110 T CY 211101110T CY 1124865 T1 CY1124865 T1 CY 1124865T1
Authority
CY
Cyprus
Prior art keywords
unions
new
new unions
treatment
mycobacteria
Prior art date
Application number
CY20211101110T
Other languages
English (en)
Inventor
Esther Porras De Francisco
Modesto Jesús Remuinan-Blanco
Marilyne BOUROTTE
Benoit Deprez
Nicolas Willand
Original Assignee
Glaxosmithkline Intellectual Property Development Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Intellectual Property Development Limited filed Critical Glaxosmithkline Intellectual Property Development Limited
Publication of CY1124865T1 publication Critical patent/CY1124865T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Η εφεύρεση αφορά σε ενώσεις του Τύπου (Ι) και χρήση αυτών στη θεραπεία, για παράδειγμα στη θεραπεία μυκοβακτηριακών μολύνσεων ή στη θεραπεία ασθενειών που προκαλούνται με μυκοβακτηρίδιο, όπως φυματίωσης.
CY20211101110T 2017-08-16 2021-12-17 Νεες ενωσεις CY1124865T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17382570 2017-08-16
PCT/EP2018/072144 WO2019034701A1 (en) 2017-08-16 2018-08-15 NEW COMPOUNDS

Publications (1)

Publication Number Publication Date
CY1124865T1 true CY1124865T1 (el) 2022-11-25

Family

ID=59713958

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20211101110T CY1124865T1 (el) 2017-08-16 2021-12-17 Νεες ενωσεις

Country Status (21)

Country Link
US (2) US11969423B2 (el)
EP (1) EP3668853B1 (el)
JP (1) JP7183270B2 (el)
KR (1) KR102657861B1 (el)
CN (1) CN111225910B (el)
AU (1) AU2018317805B2 (el)
BR (1) BR112020003221A2 (el)
CA (1) CA3072839A1 (el)
CY (1) CY1124865T1 (el)
DK (1) DK3668853T3 (el)
ES (1) ES2902600T3 (el)
HR (1) HRP20211894T1 (el)
HU (1) HUE057050T2 (el)
LT (1) LT3668853T (el)
PL (1) PL3668853T3 (el)
PT (1) PT3668853T (el)
RS (1) RS62718B1 (el)
RU (1) RU2767652C2 (el)
SI (1) SI3668853T1 (el)
WO (1) WO2019034701A1 (el)
ZA (1) ZA202000586B (el)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10250080A1 (de) 2002-10-25 2004-05-13 Boehringer Ingelheim Pharma Gmbh & Co. Kg Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
FR2903405B1 (fr) 2006-07-04 2011-09-09 Pasteur Institut Composes a effet potentialisateur de l'activite de l'ethionamide et leurs applications
CA2673580C (en) 2006-12-29 2015-11-24 Abbott Gmbh & Co. Kg Carboxamide compounds and their use as calpain inhibitors
FR2939135B1 (fr) * 2008-12-02 2010-12-03 Galderma Res & Dev Nouveaux composes 4-(azacycloalkyl)-benzene-1,3-diol comme inhibiteurs de la tyrosinase, leur procede de preparation et leur utilisation en medecine humaine ainsi qu'en cosmetique
EP2771338A2 (en) 2011-10-25 2014-09-03 Université de Droit et de la Santé de Lille 2 1, 2, 4 - oxadiazole derivatives as ethr inhibitors for use in the treatment tuberculosis
FR3000065A1 (fr) * 2012-12-21 2014-06-27 Univ Lille Ii Droit & Sante Composes bicycliques ayant une activite potentialisatrice de l'activite d'un antibiotique actif contre les mycobacteries-composition et produit pharmaceutiques comprenant de tels composes

Also Published As

Publication number Publication date
RU2020109672A3 (el) 2021-10-18
HRP20211894T1 (hr) 2022-08-19
ES2902600T3 (es) 2022-03-29
EP3668853A1 (en) 2020-06-24
WO2019034701A1 (en) 2019-02-21
CN111225910B (zh) 2023-03-24
JP2020531576A (ja) 2020-11-05
DK3668853T3 (da) 2021-12-06
CA3072839A1 (en) 2019-02-21
AU2018317805B2 (en) 2021-04-15
LT3668853T (lt) 2022-03-10
KR20200041345A (ko) 2020-04-21
RU2020109672A (ru) 2021-09-16
US20200253967A1 (en) 2020-08-13
ZA202000586B (en) 2021-08-25
EP3668853B1 (en) 2021-09-29
AU2018317805A1 (en) 2020-02-20
JP7183270B2 (ja) 2022-12-05
RS62718B1 (sr) 2022-01-31
PL3668853T3 (pl) 2022-01-31
PT3668853T (pt) 2021-12-02
US11969423B2 (en) 2024-04-30
BR112020003221A2 (pt) 2020-10-06
CN111225910A (zh) 2020-06-02
KR102657861B1 (ko) 2024-04-17
HUE057050T2 (hu) 2022-04-28
SI3668853T1 (sl) 2022-02-28
RU2767652C2 (ru) 2022-03-18
US20240307385A1 (en) 2024-09-19

Similar Documents

Publication Publication Date Title
CY1125436T1 (el) Αναστολεις dna-pk
CY1123381T1 (el) Συνθεσεις που περιεχουν βακτηριακα στελεχη
CO2021005987A2 (es) Compuestos de anillo fusionado
CY1125136T1 (el) Συνθεσεις που περιλαμβανουν βακτηριακα στελεχη
CO2021003036A2 (es) Compuestos de anillo fusionado
CY1124407T1 (el) Ενωσεις αναστολεα αυτοταξινης
CY1122148T1 (el) Συνθεσεις που περιεχουν βακτηριακα στελεχη
CY1124798T1 (el) Υποκατεστημενα παραγωγα καρβονουκλεοζιδιων χρησιμα ως παραγοντες κατα των καρκινων
CY1121473T1 (el) Συνθεσεις που περιλαμβανουν βακτηριακα στελεχη
EA202091508A1 (ru) 6-азаиндольные соединения
CR20180541A (es) Inhibidores de bromodominios
EA201790273A1 (ru) Флагеллиновые композиции и их применение
CY1125047T1 (el) Διεργασιες για την παρασκευη ενωσεων τυπου οξαθειαζινης
CY1125150T1 (el) Ενωσεις φαινυλο-2-υδροξυ-ακετυλαμινο-2-μεθυλο-φαινυλιου
CY1122957T1 (el) 1η-πυραζολο[4,3-β]πυριδινες ως αναστολεις ρdε1
CY1120751T1 (el) Αναστολεις ετεροδικυκλοαρυλιου του rorc2 και μεθοδοι χρησης αυτων
EA201692091A1 (ru) Хиноксалиновые соединения и их применение
CY1120535T1 (el) Δοτες νιτροξυλιου με βελτιωμενο θεραπευτικο δεικτη
CY1123231T1 (el) Ενωσεις τετραϋδροπυριμιδοδιαζεπινης και τετραϋδροπυριδοδιαζεπινης για θεραπεια πονου και καταστασεων σχετικων με τον πονο
CY1124338T1 (el) Αναστολεις 3-φωσφογλυκερικης αφυδρογονασης και χρησεις αυτων
EA201891644A1 (ru) Антибактериальные соединения и их применение
PL410665A1 (pl) Inhibitory arginazy oraz ich zastosowania terapeutyczne
CY1121334T1 (el) Αναστολεας κινασης aurora a
EA201891586A1 (ru) Антипролиферативные соединения и их фармацевтические композиции и применения
CY1124529T1 (el) Ενωσεις λευκοχρυσου λειτουργικοποιημενες με μονομηλεινιμιδιο για θεραπεια καρκινου